A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
This study is a randomized, double-blind, multi-center, phase III clinical study comparing the clinical efficacy and safety of HLX10 or placebo combined with chemotherapy in first-line treatment of locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients.This study consists of three periods, screening period (28 days), treatment period and follow-up period (including safety follow-up, survival follow-up).Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria.
Esophageal Squamous Cell Carcinoma
DRUG: HLX10 100 mg in 10 ml Injection|DRUG: Placebos
PFS, Progression-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1), from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years|OS, Overall survival (OS), from the date of first dose unitl the date of death from any cause，assessed up to 2 years
PFS, Progression-free survival (assessed by independent radiological review committee (IRRC) based on iRECIST，by the investigators based on RECIST v1.1)), from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years|ORR, Objective response rate (assessed by independent radiological review and the investigators based on RECIST v1.1)), up to 2 years|Duration of response, Duration of response, from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years
This study is a randomized, double-blind, multi-center, phase III clinical study comparing the clinical efficacy and safety of HLX10 or placebo combined with chemotherapy in first-line treatment of locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients.This study consists of three periods, screening period (28 days), treatment period and follow-up period (including safety follow-up, survival follow-up).Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria.